DE102009034150A1 - Adsorbens zur Adsorption von Hepcidin - Google Patents
Adsorbens zur Adsorption von Hepcidin Download PDFInfo
- Publication number
- DE102009034150A1 DE102009034150A1 DE102009034150A DE102009034150A DE102009034150A1 DE 102009034150 A1 DE102009034150 A1 DE 102009034150A1 DE 102009034150 A DE102009034150 A DE 102009034150A DE 102009034150 A DE102009034150 A DE 102009034150A DE 102009034150 A1 DE102009034150 A1 DE 102009034150A1
- Authority
- DE
- Germany
- Prior art keywords
- hepcidin
- blood
- adsorbent
- conduit means
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title claims abstract description 44
- 102000018511 hepcidin Human genes 0.000 title claims abstract description 39
- 108060003558 hepcidin Proteins 0.000 title claims abstract description 39
- 229940066919 hepcidin Drugs 0.000 title claims abstract description 39
- 239000003463 adsorbent Substances 0.000 title claims abstract description 30
- 238000001179 sorption measurement Methods 0.000 title description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 30
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 23
- 229910052742 iron Inorganic materials 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 13
- 208000007502 anemia Diseases 0.000 claims abstract description 12
- 239000003446 ligand Substances 0.000 claims abstract description 12
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 8
- 239000011159 matrix material Substances 0.000 claims abstract description 8
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 5
- 230000005593 dissociations Effects 0.000 claims abstract description 5
- 239000011148 porous material Substances 0.000 claims description 23
- 210000002381 plasma Anatomy 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 14
- 210000001124 body fluid Anatomy 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 239000010839 body fluid Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 7
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 6
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 6
- 101800003310 Hepcidin-25 Proteins 0.000 claims description 5
- 102400001151 Hepcidin-25 Human genes 0.000 claims description 5
- 238000001631 haemodialysis Methods 0.000 claims description 5
- 230000000322 hemodialysis Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229920000620 organic polymer Polymers 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 210000000601 blood cell Anatomy 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 7
- 229910052753 mercury Inorganic materials 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108091006976 SLC40A1 Proteins 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 201000000361 Hemochromatosis type 2 Diseases 0.000 description 1
- 101800003308 Hepcidin-20 Proteins 0.000 description 1
- 102400001150 Hepcidin-20 Human genes 0.000 description 1
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000002924 oxiranes Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- External Artificial Organs (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009034150A DE102009034150A1 (de) | 2009-07-20 | 2009-07-20 | Adsorbens zur Adsorption von Hepcidin |
| JP2012520933A JP5898615B2 (ja) | 2009-07-20 | 2010-07-15 | ヘプシジンの吸着用の吸着剤 |
| US13/321,329 US8915875B2 (en) | 2009-07-20 | 2010-07-15 | Adsorbents for the adsorption of hepcidin |
| CN201080032425.0A CN102549439B (zh) | 2009-07-20 | 2010-07-15 | 用于吸附铁调素的吸附剂 |
| EP10735203.1A EP2457097B1 (de) | 2009-07-20 | 2010-07-15 | Adsorbens zur adsorption von hepcidin |
| PCT/EP2010/004303 WO2011009555A1 (de) | 2009-07-20 | 2010-07-15 | Adsorbens zur adsorption von hepcidin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009034150A DE102009034150A1 (de) | 2009-07-20 | 2009-07-20 | Adsorbens zur Adsorption von Hepcidin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102009034150A1 true DE102009034150A1 (de) | 2011-01-27 |
Family
ID=42797095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102009034150A Ceased DE102009034150A1 (de) | 2009-07-20 | 2009-07-20 | Adsorbens zur Adsorption von Hepcidin |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8915875B2 (https=) |
| EP (1) | EP2457097B1 (https=) |
| JP (1) | JP5898615B2 (https=) |
| CN (1) | CN102549439B (https=) |
| DE (1) | DE102009034150A1 (https=) |
| WO (1) | WO2011009555A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014503187A (ja) * | 2010-10-29 | 2014-02-13 | ノクソン ファーマ エージー | 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用 |
| SE1200356A1 (sv) * | 2011-10-30 | 2013-05-01 | Kurt Nilsson | Polymerbaserad produkt och användning |
| DE102012025164A1 (de) * | 2012-12-21 | 2014-06-26 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur Entfernung proteingebundener Toxine aus Blutplasma |
| US9585996B2 (en) * | 2014-04-02 | 2017-03-07 | Human Biomed, Inc. | Blood purifying filter and blood purifying apparatus |
| JP6910033B2 (ja) * | 2016-08-01 | 2021-07-28 | 株式会社カネカ | カルシプロテインパーティクルの吸着材、および吸着除去システムとその利用方法 |
| JP7429343B2 (ja) | 2018-01-05 | 2024-02-08 | パス イーエックス，インク． | 流体からの疾患材料の捕捉および除去のためのデバイス |
| US20190247560A1 (en) * | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| JP7518852B2 (ja) * | 2019-03-26 | 2024-07-18 | シアー， インコーポレイテッド | 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0424698A1 (de) | 1989-10-03 | 1991-05-02 | Fresenius AG | Zur Eliminierung von Biomakromolekülen insbesondere LDL und Endotoxinen, aus Vollblut in extrakorporalem Kreislauf geeignetes Adsorbens |
| WO2008097461A2 (en) | 2007-02-02 | 2008-08-14 | Amgen Inc | Hepcidin and hepcidin antibodies |
| WO2009044284A1 (en) | 2007-10-02 | 2009-04-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies specific for human hepcidin |
| WO2009058797A1 (en) | 2007-11-02 | 2009-05-07 | Eli Lilly And Company | Anti-hepcidin antibodies and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56145858A (en) * | 1980-04-15 | 1981-11-12 | Unitika Ltd | Purifier for body fluid |
| JPS5897366A (ja) * | 1981-12-08 | 1983-06-09 | 旭化成株式会社 | 血液及び体液物質の除去装置 |
| CN1019132B (zh) * | 1985-03-29 | 1992-11-18 | 格鲁波莱佩蒂特公司 | 抗尿激酶单克隆抗体，带有它的基质，其试验方法和使用它的生化试验药盒 |
| US5476715A (en) * | 1989-10-03 | 1995-12-19 | Fresenius Ag | Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits |
| US6416487B1 (en) * | 1997-07-30 | 2002-07-09 | Renal Tech International Llc | Method of removing beta-2 microglobulin from blood |
| DE19913707A1 (de) | 1999-03-26 | 2000-10-05 | Privates Inst Bioserv Gmbh | Immunadsorber zur Sepsistherapie |
| EP1392345B2 (en) | 2001-05-25 | 2018-02-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| CN1116926C (zh) * | 2001-09-21 | 2003-08-06 | 大连理工大学 | 用于治疗高胆红素血症的免疫吸附材料 |
| SE0201257D0 (sv) * | 2002-04-25 | 2002-04-25 | Medical Invest In Sweden Ab | Improved Separation |
| CN1408442A (zh) | 2002-09-09 | 2003-04-09 | 天津医科大学总医院 | 全血灌流吸附治疗用吸附剂 |
| RU2359268C2 (ru) * | 2002-11-19 | 2009-06-20 | ДиАрДжи ИНТЕРНЭШНЛ, ИНК. | Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение |
| US8017737B2 (en) * | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| DE10324668A1 (de) * | 2003-05-30 | 2004-12-23 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur extrakorporalen Bestrahlung einer Bilirubin enthaltenden Flüssigkeit und Verfahren hierfür |
| ES2433280T3 (es) | 2004-10-20 | 2013-12-10 | Hans-Werner Prof. Dr. Heinrich | Adsorbente inmunológico para el tratamiento de inflamaciones |
| CN101279242A (zh) * | 2008-05-20 | 2008-10-08 | 大连理工大学 | 用于抗体清除的血液净化吸附剂 |
-
2009
- 2009-07-20 DE DE102009034150A patent/DE102009034150A1/de not_active Ceased
-
2010
- 2010-07-15 CN CN201080032425.0A patent/CN102549439B/zh not_active Expired - Fee Related
- 2010-07-15 EP EP10735203.1A patent/EP2457097B1/de not_active Not-in-force
- 2010-07-15 JP JP2012520933A patent/JP5898615B2/ja not_active Expired - Fee Related
- 2010-07-15 US US13/321,329 patent/US8915875B2/en active Active
- 2010-07-15 WO PCT/EP2010/004303 patent/WO2011009555A1/de not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0424698A1 (de) | 1989-10-03 | 1991-05-02 | Fresenius AG | Zur Eliminierung von Biomakromolekülen insbesondere LDL und Endotoxinen, aus Vollblut in extrakorporalem Kreislauf geeignetes Adsorbens |
| WO2008097461A2 (en) | 2007-02-02 | 2008-08-14 | Amgen Inc | Hepcidin and hepcidin antibodies |
| WO2009044284A1 (en) | 2007-10-02 | 2009-04-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies specific for human hepcidin |
| WO2009058797A1 (en) | 2007-11-02 | 2009-05-07 | Eli Lilly And Company | Anti-hepcidin antibodies and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| DIN 66 133 |
| DIN Norm 66 133 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102549439A (zh) | 2012-07-04 |
| EP2457097B1 (de) | 2015-09-09 |
| WO2011009555A1 (de) | 2011-01-27 |
| CN102549439B (zh) | 2016-01-20 |
| US20120063954A1 (en) | 2012-03-15 |
| JP2012533582A (ja) | 2012-12-27 |
| US8915875B2 (en) | 2014-12-23 |
| EP2457097A1 (de) | 2012-05-30 |
| JP5898615B2 (ja) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2457097B1 (de) | Adsorbens zur adsorption von hepcidin | |
| DE69530682T2 (de) | Methode zur Isolierung und Reinigung eines Biomakromoleküls | |
| DE69605395T2 (de) | Vorrichtung zum extrakoporealen Entfernen von Toxinen, insbesondere Zytokinen | |
| EP2101843B1 (de) | Vorrichtung zur entfernung von leukozyten aus blut | |
| EP1993631B1 (de) | Regenerierbares filter zur extrakorporalen behandlung partikelhaltiger flüssigkeiten und deren anwendung | |
| EP1326708B1 (de) | Adsorbens mit unterschiedlich modifizierten oberflächenbereichen, verfahren zu dessen herstellung und verwendung davon | |
| EP3417937B1 (de) | Hämokompatibler adsorber zur dialyse proteingebundener urämietoxine | |
| AT507847B1 (de) | Sorptionsmittel zum entfernen proteingebundener substanzen | |
| DE3412616A1 (de) | Adsorbens fuer autoantikoerper- und immunkomplexe, dieses enthaltende adsorptionsvorrichtung und dieses enthaltender blutreinigungsapparat | |
| EP1372758B1 (de) | Verfahren zur eliminierung von potentiell toxischen und/oder schädlichen stoffen | |
| EP1132128B1 (de) | Verwendung des Adsorbens zur Herstellung eines Adsorbers zum Absenken der Konzentration von Fibrinogen und/oder Fibrin | |
| EP2679302A1 (de) | Selektives Sorptionsmittel für die extrakorporale Blutreinigung | |
| EP1132129B1 (de) | Verfahren zum Herstellen eines Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Adsorbens und Verwendung des Adsorbens zur Herstellung eines Adsorbers | |
| EP2254619B1 (de) | Bioäquivalenzdialyse | |
| DE10258944A1 (de) | Vorrichtung zur Entfernung von bakteriellen Lipopolysacchariden oder/und Lipoteichonsäuren aus proteinhaltigen Flüssigkeiten sowie deren Verwendung zur Behandlung von Sepsis | |
| EP1003787B1 (de) | Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen | |
| WO2006120226A1 (de) | Stabilisatormoleküle-abgereicherte albuminlösung | |
| EP0321597B1 (de) | Selektives Adsorbens zur Bindung von Lipoproteinen niedriger Dichte | |
| DE102005061715A1 (de) | Prozess zur Entfernung von C-reactivem Protein aus biologischen Flüssigkeiten durch Apherese | |
| EP3762065A1 (de) | Vereinfachte regeneration von apheresesäulen | |
| DE10325304B3 (de) | Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin in Blut oder Blutplasma, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE202006004182U1 (de) | Regenerierbarer Filter zur extrakorporalen Behandlung partikelhaltiger Flüssigkeiten und deren Anwendung | |
| DD252547A1 (de) | Selektives adsorbens zur bindung von lipoproteinen niedrieger dichte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| R002 | Refusal decision in examination/registration proceedings | ||
| R003 | Refusal decision now final |